ALT stock news

ALT stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.

See the full wire

18 wire items

2026-10-27 12:23:00 UTC#521195duplicateconfirmednews

Altimmune board adds Peter Greenleaf and Alex Howarth; three directors to retire after 2027 annual meeting

tradingviewimportance 0.30trust 0.70Altimmune, Inc. +0.10Peter Greenleaf +0.20Alex Howarth +0.20+2 entities

2026-10-27 12:06:00 UTC#520990newconfirmedpress release

Altimmune appoints Peter Greenleaf and Alex Howarth to board of directors

dow_jonesimportance 0.30trust 0.90Altimmune, Inc. +0.20Peter Greenleaf +0.20Alex Howarth +0.20

2026-09-30 15:20:15 UTC#392649newconfirmednews

Altimmune advances pemvidutide phase III trials for MASH and alcohol-related liver disease

quartrimportance 0.40trust 0.50Altimmune, Inc. +0.40Pemvidutide +0.40

2026-09-10 14:26:08 UTC#292905newconfirmednews

Altimmune advances Phase III MASH trial enrollment for pemvidutide, highlights strong Phase II data

quartrimportance 0.40trust 0.60Altimmune, Inc. +0.40pemvidutide +0.40

2026-08-12 20:06:10 UTC#167453newconfirmednews

Altimmune Q2 2026 net loss widens to $22.8M on higher R&D and G&A expenses

quartrimportance 0.40trust 0.70Altimmune, Inc. -0.20pemvidutide +0.30

2026-08-12 18:38:11 UTC#167099newconfirmednews

Altimmune sets 2029 target for PERFORMA Phase III MASH data readout, advances AUD Phase III planning

seeking alphaimportance 0.40trust 0.70Altimmune, Inc. +0.20

2026-08-12 13:31:00 UTC#165533duplicateconfirmednews

Altimmune Inc reports Q2 2026 adjusted loss of $0.12 per share, beating analyst consensus of $0.14 loss

reutersimportance 0.30trust 0.90Altimmune, Inc. +0.30

2026-08-12 11:52:13 UTC#164845duplicateconfirmednews

Altimmune's pemvidutide continues Phase 3 trials for MASH and ALD following positive Phase 2 results

quartrimportance 0.30trust 0.50Altimmune, Inc. +0.60Pemvidutide +0.60

2026-08-12 11:40:06 UTC#164756newconfirmednews

Altimmune initiates Phase 3 MASH trial, reports positive Phase 2 AUD results, and completes $225M public offering

quartrimportance 0.50trust 0.70Altimmune, Inc. +0.50

2026-08-12 11:38:12 UTC#164740newconfirmednews

Altimmune Q2 GAAP EPS of -$0.12 beats consensus estimates by $0.02

seeking alphaimportance 0.40trust 0.80Altimmune, Inc. +0.30

2026-08-12 11:30:00 UTC#164712newconfirmednews

Altimmune reports Q2 2026 loss of $0.12 per share

dow_jonesimportance 0.40trust 0.90Altimmune, Inc. +0.20

2026-08-10 13:51:07 UTC#153048newconfirmednews

Altimmune (ALT) Q2 2026 Earnings Preview: Analysts Expect $0.14 Loss Per Share

reutersimportance 0.30trust 0.80Altimmune, Inc. -0.10London Stock Exchange Group plc 0

2026-08-03 12:15:09 UTC#116589newconfirmedpress release

Altimmune initiates Phase 3 PERFORMA trial of pemvidutide for MASH, 52-week data expected in 2029

reutersimportance 0.60trust 0.90Altimmune, Inc. +0.50Pemvidutide +0.50PERFORMA +0.50

2026-07-29 11:35:00 UTC#93619newconfirmednews

Analyst Price Target Revisions: ABBV, AMGN, BAC, BA, and Others See Upward Adjustments

walter_bloombergimportance 0.40trust 0.50AbbVie Inc. +0.30Acadia Healthcare Company, Inc. +0.30Altimmune, Inc. +0.30+2 entities

2026-07-28 22:20:03 UTC#90577newconfirmednews

Altimmune, Inc. average analyst price target raised to $17.22, implying 482% upside

tradingviewimportance 0.40trust 0.70Altimmune, Inc. +0.40FactSet Research Systems Inc. 0

2026-07-28 14:08:37 UTC#88206duplicateconfirmednews

Altimmune's RECLAIM Phase II trial for pemvidutide in AUD meets primary and secondary endpoints

quartrimportance 0.40trust 0.70Altimmune, Inc. +0.80Pemvidutide +0.80RECLAIM +0.80+2 entities

2026-07-28 12:29:00 UTC#87585duplicateconfirmednews

Altimmune shares rise 9.5% premarket on positive Phase 2 trial results for alcohol-use disorder drug pemvidutide

dow_jonesimportance 0.40trust 0.80Altimmune, Inc. +0.70Pemvidutide +0.70U.S. Food and Drug Administration +0.10+1 entities

2026-07-28 11:29:29 UTC#87156newconfirmednews

Altimmune shares rise on positive mid-stage trial data showing GLP-1 reduces alcohol consumption

seeking alphaimportance 0.50trust 0.60Altimmune, Inc. +0.60